Latest News

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
23rd September, 2020
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease PARIS, France and… READ MORE
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
Vivet’s lead program, VTX-801 for Wilson Disease, highlighted during Pfizer’s Investor Day September 15th 2020
15th September, 2020
Vivet Therapeutics’ lead program, VTX-801 for Wilson Disease, was highlighted during Pfizer’s Investor Day September 15th 2020. We are very… READ MORE
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation
1st June, 2020
Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation. PARIS, France June 1st, 2020,… READ MORE
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
Happy to share the March 2020 Info Wilson newsletter from ABPWilson!
10th April, 2020
Vivet is very happy to share the March 2020 Info Wilson newsletter from ABPWilson (L’Association Bernard Pépin pour la Maladie… READ MORE
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
Vivet Announces Publication in Nature Communications of VTX-803 Preclinical Data
16th December, 2019
Vivet Announces Publication in Nature Communications of Preclinical Data from VTX-803, Vivet’ novel therapeutic in development for the treatment of… READ MORE
PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS
PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS
20th March, 2019
PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS Pfizer and Vivet to collaborate on development of potential… READ MORE
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board
Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board
12th June, 2018
PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today… READ MORE
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies
FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies
28th September, 2017
PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one… READ MORE
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives EU and US ODD
Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives EU and US ODD
27th September, 2017
PARIS, France September 26th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European… READ MORE
FDA news : Cellular & Gene Therapy Guidances
FDA news : Cellular & Gene Therapy Guidances
2nd April, 2017
A useful resource of Cellular & Gene Therapy Guidance Documents READ MORE
EMA News
EMA News
2nd April, 2017
This section of the website provides information for companies and individuals involved in developing and marketing medicines for human use… READ MORE
Gene Therapy of Liver Diseases
Gene Therapy of Liver Diseases
2nd April, 2017
In Europe, a disease is defined as rare when it affects fewer than one out of every 2,000 people. However,… READ MORE
Vivet Therapeutics raises €37.5 million in Series A financing round
Vivet Therapeutics raises €37.5 million in Series A financing round
1st April, 2017
Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases READ MORE
Show Archived
Vivet Annual Meeting in Washington DC
Vivet Annual Meeting in Washington DC
2nd April, 2017
Vivet Therapeutics Announces Presentation at the Upcoming American Society For Gene And Cell Therapy (ASGCT) Annual Meeting in Washington DC READ MORE